SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc. (Nasdaq:ZGNX) is launching a new and improved SUMAVEL ® DosePro ® Migraine Toolbox to support patient education and empowerment. The Migraine Toolbox highlights the importance of having the appropriate medication on hand in the patient's "treatment toolbox" to address the specific migraine attack the patient is experiencing.
Dr. Stephen Silberstein, Professor and Director of the Jefferson Headache Center at Thomas Jefferson University, Philadelphia, Pennsylvania, said, "The frequency, intensity and speed of onset of migraines can vary greatly for patients so it is vital that migraine sufferers follow U.S. Headache Consortium Migraine treatment guidelines which recommend having access to a toolbox of treatment options. This includes medication such as oral and injectable triptan therapies that are fast-acting, convenient and easy-to use for more aggressive migraine attacks. In addition, education regarding treatment options is a key component of every migraine patient's treatment plan."
The Migraine Toolbox reinforces the role of SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan injection) in treating specific types of migraine attacks such as those that cause patients to wake up or throw up, or require a fast-acting backup plan when migraines come on suddenly or recur. A National Headache Foundation survey of 500 migraine sufferers found that the majority of sufferers (54 percent) said their prescription oral migraine medication is not useful for every migraine attack, yet less than 20 percent of such sufferers use backup prescribed medication when an oral tablet is not an option. 1Roger L. Hawley, chief executive officer of Zogenix, said, "Migraine is more than a headache. The Migraine Toolbox has become a standard part of migraine care in physician offices across the country where they are using the national migraine treatment guidelines to enhance outcomes. The patient focus is on attack-based care which empowers the patient to select the appropriate form of triptan treatment based on the severity, symptoms and circumstances of that specific attack. While oral triptans can often be the right choice, many patients have specific attacks where they know their oral medication may not give the pain-free outcome they need to be functional. The Toolbox has become an excellent education resource for migraine suffers and for these physicians who follow the treatment guidelines. Our goal is to keep making the Migraine Toolbox better based on customer feedback."